Efficacy of Azithromycin in Treatment of Bronchiectasis

Inclusion Criteria: * Have provided written informed consent to participate in the study in accordance with the local ethics committee regulations * Have a confirmed diagnosis of bronchiectasis (by HRCT) Aged 18 years or over Have chronic sputum production, defined as a greater than 45 mililitres volume produced in the 1 week prior to study entry. * Be able to perform reproducible spirometry * Be in a relatively stable disease state in the 6 weeks prior to entry, as defined by the absence of the following: respiratory exacerbations requiring hospitalisation, change in cough and/or sputum production, new or increased hemoptysis, more than 10% weight loss, use of additional antibiotic courses Exclusion Criteria: * Subjects will be excluded if one or more of the following criteria occur. The subject: Is an investigator, or an immediate family member of an investigator * Has a confirmed diagnosis of cystic fibrosis, as evidenced by genetic analysis or a sweat test result more than 60mmol/L * Has a primary immunodeficiency Is a pregnant or lactating female Has had a respiratory exacerbation requiring hospitalisation or additional course of antibiotics in the 6 weeks prior to study entry * Has been prescribed or used oral steroids on any occasion for the 3 months prior to study entry. * Has been using mucolytic agents on any occasion for the 2 months prior to study entry Has active tuberculosis * Has an active malignancy, including melanoma (other skin carcinomas excluded) * Has a history of significant liver disease or insufficiency Has a significant history of drug abuse (including alcohol abuse) or mental illness Has a known intolerance or allergy to macrolides * Has been participating in another interventional drug study in the 3 months prior to enrolment into this study